Affordable Access

Access to the full text

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial

Authors
  • Cho, A-Ra1
  • Choi, Won-Jun2
  • Kwon, Yu-Jin1
  • Lee, Hye Sun3
  • Ahn, Sung Gwe4
  • Lee, Ji-Won4
  • 1 Yong-in Severance Hospital, Yonsei University College of Medicine, Yong‑in, 16995
  • 2 Yonsei University, Seoul, 03722
  • 3 Yonsei University College of Medicine, Seoul, 06273
  • 4 Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06273
Type
Published Article
Journal
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Publisher
Dove Medical Press
Publication Date
Sep 29, 2020
Volume
13
Pages
3325–3335
Identifiers
DOI: 10.2147/DMSO.S269237
PMID: 33061494
PMCID: PMC7532917
Source
PubMed Central
Keywords
License
Green

Abstract

Introduction The objective of this pilot randomized controlled trial was to investigate the combined effect of a Mediterranean diet and naltrexone/bupropion treatment on body weight, metabolic parameters, and quality of life in overweight or obese breast cancer survivors. Methods Forty-four breast cancer survivors were randomly assigned to receive the Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet+NB group) or the Mediterranean diet alone (breast cancer survivor MeDiet-only group). Twenty-eight age-matched non-cancer patients were instructed to consume the Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet+NB group). After the 8-week intervention, changes in body weight, metabolic parameters, nutrient intake, and quality of life of the three groups were assessed. Results Significant weight loss of 2.8 kg was noted for the breast cancer survivor MeDiet+NB group, 1.8 kg for the breast cancer survivor MeDiet-only group, and 2.5 kg for the non-cancer MeDiet+NB group after 8 weeks ( P < 0.05 versus baseline by Wilcoxon’s signed-rank test). All three groups also exhibited significantly lower fasting glucose, insulin, and homeostasis model assessment of insulin resistance levels ( P < 0.05). Quality of life as assessed by self-reported questionnaires showed improvement in all participants ( P < 0.05). However, there were no significant differences of changes in body weights, metabolic parameters, and quality of life among the three groups or between the MeDiet+NB and MeDiet-only groups. Conclusion We found that the Mediterranean diet, with or without naltrexone/bupropion treatment, facilitates weight loss, improves metabolic parameters, and increases quality of life. The combination of the Mediterranean diet with naltrexone/bupropion treatment did not produce superior changes when compared to the Mediterranean diet alone. Trial Registration This trial was retrospectively registered on 10 July 2018 as NCT03581630 at ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT03581630 ).

Report this publication

Statistics

Seen <100 times